Clinical trials · North Carolina
B-cell Acute Lymphoblastic Leukemia clinical trials in North Carolina
We’re tracking 14 recruiting b-cell acute lymphoblastic leukemia studies with a site in North Carolina — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in North Carolina
- NCT05082519RecruitingPhase 2
Calorie restriction and exercise to improve leukemia treatment in young patients
This study tests whether a special diet (calorie restriction) and increased physical activity can make chemotherapy work better for young people with B-ALL. Participants will follow a monitored diet and exercise plan during their first month of treatment.
Charlotte, North CarolinaAges 7–25 - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Chapel Hill, North CarolinaAges 13–90 - NCT06124157RecruitingPhase 2
Targeted therapy plus chemo for children with Ph+ or Ph-like B-ALL
This trial tests if adding a targeted drug (dasatinib or imatinib) to a chemotherapy combination with blinatumomab works better for children and young adults with a specific genetic form of B-cell acute lymphoblastic leukemia. The goal is to see if this approach can improve treatment outcomes for patients with Philadelphia chromosome-positive or ABL-class Ph-like B-ALL.
Asheville, North CarolinaAges 1 year–46 years - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Chapel Hill, North CarolinaAges 18 years+ - NCT07634653Recruiting
Strength Training for Kids with Newly Diagnosed Blood Cancer
This study tests whether strength training exercises during cancer treatment can help children with acute lymphoblastic leukemia or lymphoblastic lymphoma feel stronger and recover better. The research includes optional interviews with parents to understand how the program affects families.
Chapel Hill, North CarolinaAges 6 years+ - NCT06533748RecruitingPhase 2
New treatment for kids with B-cell leukemia or lymphoma
This trial tests a new therapy plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia or lymphoma. It aims to improve outcomes for those with higher-risk features.
Charlotte, North CarolinaAges 1–18 - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Asheville, North CarolinaAges 12 months–25 years - NCT03509961RecruitingPhase 2
Reducing total body radiation for children with leukemia transplants
This study looks at whether some children and young adults with B-ALL can safely get a transplant without total body irradiation (TBI), based on special leukemia test results. It’s meant to help lower radiation-related risks while keeping leukemia control strong.
Charlotte, North CarolinaAges 1–25 - NCT03666000RecruitingPhase 1
Testing a CD19 CAR T cell treatment for relapsed blood cancers
This Phase 1 study tests the safety and best dose of a CD19 CAR T cell therapy (azer-cel) in people whose B-cell blood cancer has returned or did not respond to treatment. It may help people with relapsed/refractory B-ALL or certain aggressive or large B-cell lymphomas, including after or before prior CAR T treatment.
Durham, North CarolinaAges 18 years+ - NCT04546399RecruitingPhase 2
Blinatumomab with or without nivolumab for first relapse ALL
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Asheville, North CarolinaAges 1–30 - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Charlotte, North CarolinaAges 1–21 - NCT05848687RecruitingPhase 1/Phase 2
Newborns with CD19 leukemia may try a combined infant therapy
This early-phase study is testing a “total therapy” treatment plan for very young babies (diagnosed within the first year of life) with certain types of leukemia that carry the CD19 marker. It may help find safer and more effective treatment for infants with this disease, especially soon after diagnosis.
Charlotte, North CarolinaAges Up to 1 year - NCT03150693RecruitingPhase 3
New treatment for young adults with CD22-positive ALL
This Phase 3 trial tests adding inotuzumab ozogamicin to standard chemotherapy for newly diagnosed CD22-positive B-cell acute lymphoblastic leukemia (ALL). It may help more patients achieve remission and reduce the risk of the leukemia coming back, while also checking safety and tolerability.
Chapel Hill, North CarolinaAges 18–39 - NCT05865301Recruiting
Outcomes after approved immunotherapy for young blood cancer patients
This study looks at the real-world results of treating certain B-cell blood cancers in children and young adults with commercially available immunotherapy. It may help doctors better understand how these treatments work for patients after relapse or when they need additional therapy.
Charlotte, North CarolinaAges Up to 26 years
Where these studies are running in North Carolina
Institutions with a site for the recruiting b-cell acute lymphoblastic leukemia studies listed above.
- UNC Lineberger Comprehensive Cancer Center · 6 studies
- Duke University Medical Center · 5 studies
- Wake Forest University Health Sciences · 5 studies
- East Carolina University · 4 studies
- Carolinas Medical Center/Levine Cancer Institute · 3 studies
- Mission Hospital · 3 studies
- Novant Health Presbyterian Medical Center · 3 studies
- Levine Cancer Institute · 2 studies
What taking part in a b-cell acute lymphoblastic leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
B-cell Acute Lymphoblastic Leukemia trials in other states
Common questions
- Are there b-cell acute lymphoblastic leukemia clinical trials in North Carolina?
- Yes. We're currently tracking 14 recruiting b-cell acute lymphoblastic leukemia studies with a site in North Carolina, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a b-cell acute lymphoblastic leukemia study in North Carolina?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in North Carolina to take part?
- Not necessarily. These studies have a site in North Carolina, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a b-cell acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New b-cell acute lymphoblastic leukemia studies open in North Carolina regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.